Rheumatoid arthritis (RA) is a progressive and painful systemic inflammatory disease that preferentially attacks the synovium of the joints, leading to joint destruction, debility, and deformity. Increased understanding of the underlying pathophysiology of RA has made a remarkable difference in its treatment and prognosis. Numerous therapeutic agents with diverse targets and mechanisms have been added to the RA armamentarium, allowing for intervention at various stages in the pathogenic process of the disease. By understanding the underlying immunologic mechanisms driving RA progression, clinicians involved in the management of patients with RA will be better equipped to evaluate the clinical and pharmacologic safety, as well as the efficacy profiles of current and emerging therapies. In this RA Forum®, leading rheumatologists will integrate discussions of basic immunologic principles with current and emerging RA treatments and interactive cases, as well as discuss treatment guidelines and use of biosimilars in the clinic.
The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients with RA.
Upon successful completion of this activity, participants should be better able to:
- Examine the underlying principles of innate and adaptive immunity as they contribute to the pathophysiologic basis of rheumatic diseases and the mechanisms of action of available and emerging immune-based therapies.
- Select treatment for patients with RA based on the latest clinical evidence as well as patient characteristics, preferences and prognosis.
- Utilize evidence-based strategies to assess disease activity and alter therapy accordingly for patients with RA.
- Implement strategies to mitigate risk from biologic and immune-based therapies.
- Examine the benefits and limitations of biosimilars for management of rheumatic diseases.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this live activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.
Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.